Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Abstract
Background and aims: Over 10% of Crohn's disease (CD) patients annually lose response to infliximab. Infliximab trough levels (TL), concomitant immunosuppressants and endoscopic healing were proposed as predictors of favourable infliximab outcome.
We assessed infliximab TL measured after induction therapy as predictors of sustained clinical response. Furthermore, we tried to identify other predictors of long-term benefit of infliximab therapy.
Methods: We included CD patients treated with infliximab between October 2007 and March 2010 who responded to 3-dose induction followed by maintenance therapy and in whom blood samples taken at treatment week 14 or 22 were available in blood bank. Sustained response to infliximab was defined as absence of treatment failure due to loss of response or drug intolerance.
Results: Eighty four patients were included. Sustained response to infliximab was observed in 47 (56%) patients during a median follow-up of 25 months (14-37). lnfliximab TL>3 mu g/ml were associated with a decreased risk of treatment failure (HR 0.34; 95% Cl: 0.16-0.75), whereas the presence of antibodies against infliximab and need for corticosteroids increased this risk (HR 4.34; 95% Cl: 1.51-12.5 and HR 2.49, 95% Cl: 1.08-5.73, respectively).
No impact of concomitant thiopurines was observed, although patients receiving thiopurines had higher infliximab TL than those without immunomodulators (5.51 vs. 0.71 mu g/ml; p =0.01). Conclusion: During a median follow up of 2 years sustained response to infliximab was observed in slightly more than half of CD patients.
Infliximab TL>3 mu g/ml at the start of maintenance regime were predicative of sustained response to infliximab. (C) 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V.
All rights reserved.